Assessing Changes in Gadoxetate Metabolism by the Liver Using MRI

Quantifying the Perturbation of Gadoxetate Kinetics by Metformin and Ciclosporin With Functional Magnetic Resonance Imaging of the Liver

Identifying drugs at risk of interacting with other drugs, called drug-drug interaction (DDI), early in their development is crucial in avoiding late-stage drug development failures. The liver plays a key role in DDIs , with liver cells playing a major part in the taking up and getting rid of drugs. Currently, there is a lack of safe, widely available tools for testing DDIs in humans, particularly interactions involving liver cell transporters.

This study is part of five work packages under the TRISTAN project (Translational Imaging in Drug Safety Assessment) which aims to improve drug safety using imaging. A pilot study provided proof-of-principle that the imaging procedure, dynamic gadoxetate (a type of dye) enhanced magnetic resonance imaging (DGE-MRI), can be used to measure the effect drugs have on the liver cell transporters in humans, using Rifampicin as a test drug. This study aims to further confirm DGE-MRI as a liver imaging biomarker in humans using two different drugs known to act on these transporters.

All study procedures will be done at Sheffield Teaching Hospitals NHS Foundation Trust at the Royal Hallamshire Hospital. This is the site for University of Sheffield MRI related research. Healthy volunteer participants over the age of 18 years old will be eligible with the aim to recruit 12 volunteers. Each participant will attend 3 visits undertaken in a stepwise manner. Visit A will be for screening, consent and baseline blood tests. Visit B will include two MRI scans with gadoxetate administered at each and blood tests measuring liver function taken prior to each scan. Participants will proceed to Visit C if satisfactory images are obtained during the previous visit. Visit C will mirror Visit B, however either Metformin of Ciclosporin will be administered prior to the first scan. The study duration is three months.

Study Overview

• Status: Completed
• Conditions: Liver Dysfunction

Detailed Description

The identification of drugs at risk of drug-drug interactions (DDI) early in the drug development life cycle is key to avoid late stage drug development failures. A critical gap in current methodologies is for tools that are widely available and safe to use in humans, and specifically can distinguish between perturbation of hepatocellular uptake, excretion or both.

Dynamic gadoxetate enhanced magnetic resonance imaging (DGE-MRI) is a technique that can potentially fill this gap. The MRI contrast agent gadoxetate is used in clinical routine, it is known to be taken up in hepatocytes by transporters OATPB1 and excreted to bile by MRP2 transporters, and the respective uptake and excretion rates can be quantified with DGE-MRI using suitable MRI scans and data modelling.

Studies in animal models using DGE-MRI on 6 different drugs have clearly demonstrated various levels of drug-induced inhibition of gadoxetate uptake and excretion. Recently, a proof-of-concept study in healthy human volunteers using DGE-MRI to characterise a single drug (rifampicin) has shown a systematic 95% reduction in gadoxetate uptake and 40% reduction in excretion.

Aims

Study objectives The purpose of the current study is to expand on these previous results and use DGE-MRI to measure the inhibition of gadoxetate uptake and excretion in volunteers with two other test drugs, metformin and ciclosporin (Neoral). These drugs are selected because they are commonly used in clinical practice, have a good safety profile and are known to inhibit OATP1B1 and MRP2 function. They should therefore also produce a measurable effect on gadoxetate uptake and excretion rates. If we can show that this is indeed measurable, the results will add further evidence that these effects can be detected by DGE-MRI, improve our understanding of relevant effect size and limits of detection, and help us identify thresholds above which reduction in gadoxetate uptake or excretion would be of concern.

Study endpoints

1. The effect of a clinical dose of metformin on hepatocellular gadoxetate uptake and excretion in healthy volunteers.
2. The effect of a clinical dose of ciclosporin (Neoral) on hepatocellular gadoxetate uptake and excretion in healthy volunteers.

Long-term aims On the longer term we expect these data to help build a case that DGE-MRI can be a useful tool to assess transported-mediated DDI risk in early drug development. The study results will be included in an application to FDA's biomarker qualification program as described in a biomarker qualification plan (submitted to FDA) following acceptance by the FDA of a letter of intent outlining the rationale for this biomarker in drug development.

Methods

This is a single centre, prospective observational study including healthy volunteer participants. 6 participants will be recruited to each immediate-release metformin and ciclosporin (Neoral) drug arms (12 total). After screening and consent, each subject will attend two hospital visits no less than 7 days apart. On each visit they will undergo DGE-MRI in the morning, and once again after a 2-hour break to allow for sufficient time to measure biliary gadoxetate clearance. On the second visit one of the two test drugs will be administered before the first scan. Each DGE-MRI scan will be performed using 25% (¼) of a clinical dose of gadoxetate. Immediate-release metformin and ciclosporin (Neoral) will be used at standardised dosages (1000mg and 100mg, respectively). Blood samples will be taken before drug administration and before each scan for comparative assessment with liver function tests (LFT).

The work is outlined below.

1. Visit A, Screening: After eligibility screening, informed consent for participation will be taken. A clinical examination including observations and blood tests for renal and liver function will be taken. If renal function shows eGFR<30mL/min/1.73m2, liver function parameters exceed laboratory normal values or clinical examination findings are not compatible with the inclusion criteria, the participants will be removed from the study.
2. Visit B, Baseline Scan: Participants will have two DGE-MRI scans with 25% (¼) standard clinical dose of gadoxetate administered at each. Blood samples (<5mL) will be taken before each scan to assess liver function.
3. Visit C, Treatment Scan: After giving informed consent, participants will receive a single dose of either metformin or ciclosporin (Neoral) followed by an initial DGE-MRI scan at 25% (¼) standard clinical dose of gadoxetate. Metformin (1000mg) or ciclosporin (100mg, Neoral) will be administered 2 and 1 hour before gadoxetate injection, respectively. This is followed by another DGE-MRI at the same dose after a break of 60-120 minutes. LFTs (<5mL blood) will be taken before metformin/ciclosporin (Neoral) administration, and also before each scan (totalling 3 blood tests).

Analyses

All images will be reviewed by a qualified abdominal radiologist to check for incidental findings.

Gadoxetate uptake and excretion kinetic rate constants will be measured with and without the drug for all participants. The primary outcome measure is the effect size of the drug on uptake and excretion.

The primary analyses will be done at the University of Sheffield.

Safety

The modelling and use of gadoxetate as a research biomarker was established in the proof-of-concept study conducted at the University of Leeds. Gadoxetate will be used at 25% (¼) standard clinical dose for each scan. This dose was established in the precursor study as the requisite dose to enable analyses of gadoxetate kinetics whilst not exposing participants unnecessarily to higher doses of the gadoxetate. At 25% of standard clinical dose, gadoxetate is not licensed for the diagnostic use. The administration of gadoxetate will be authorised by the clinical lead, Dr Benjamin Rea.

Both Metformin and Ciclosporin have an excellent safety profile and record, and therefore the risk posed to a healthy volunteer with no history of polypharmacy or comorbidities from a one off dose, is negligible. Routine clinical exclusions will be applied pertaining to the administration of gadoxetate, metformin and ciclosporin (Neoral) as well as contraindications to MRI imaging.

There will be no monitoring procedures undertaken following completion of this study but the research fellow will remain contactable following completion of the study for further queries.

• Study Type: Observational
• Enrollment (Actual): 12

Contacts and Locations

Study Locations

• United Kingdom
  • Sheffield, United Kingdom
    • Royal Hallamshire Hospital
  • Sheffield, United Kingdom, S10 2RX
    • University of Sheffield, POLARIS, 18 Claremont Crescent

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Healthy volunteers responding to a call for study participation (online advertisements).

Description

Inclusion criteria

• Able to provide informed consent
• Age above 18 years
• Able to attend for all scheduled visits
• Able to adhere to instructions on pre-scan food and drinks intake
• Able to lie flat for the duration of the scan

Exclusion criteria

Standard MRI exclusions, including:

• No history of liver or kidney disease
• No history of heart failure
• No history of uncontrolled hypertension
• No history of malignancy or premalignant conditions, past or present
• No current uncontrolled infections
• Not currently pregnant
• Not currently breastfeeding
• No regular prescribed medication, except the oral contraceptive pill
• Cochlear implant
• Aneurysm clips
• Neurological stimulator
• Implanted cardiac devices (ICD, PPM, loop recorders, or any others)
• Metal heart valve
• History of retained metal foreign bodies
• Other implanted metal device which prevents MR imaging
• Claustrophobia
• Weight exceeding 140 kg
• History or allergic reaction to MRI contrast agent

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To evaluate the rate of gadoxetate uptake	quantitative variables extracted from the MRI data. 95% CI on the mean effect size of uptake rate khe (mL/min/100mL)	Visit B which is performed at baseline, Visit C which is performed within 56 days of baseline visit B
To evaluate the rate of gadoxetate excretion	quantitative variables extracted from the MRI data. 95% CI on the mean effect size of excretion rate kbh (mL/min/100mL	Visit B which is performed at baseline, Visit C which is performed within 56 days of baseline visit B

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluate effect size of gadoxetate uptake rates as measured by DGE-MRI in response to test drug administration.	Use of quantitative variables extracted from MRI data Effect size (%) calculated as = 100* (rate constant with drug - rate constant without drug)/(rate constant without drug)	Visit B which is performed at baseline, Visit C which is performed within 56 days of baseline visit B
Evaluate effect size of gadoxetate clearance rates as measured by DGE-MRI in response to test drug administration.	Use of quantitative variables extracted from MRI data Effect size (%) calculated as = 100* (rate constant with drug - rate constant without drug)/(rate constant without drug)	Visit B which is performed at baseline, Visit C which is performed within 56 days of baseline visit B
Evaluate liver function test results in response to test drug administration.	Quantitative variables from blood test results; AST (IU per Litre), ALT (IU per Litre), ALP(IU per Litre), GGT(IU per Litre) and bilirubin (umol per litre)	Visit B which is performed at baseline, Visit C which is performed within 56 days of baseline visit B
Evaluate effect size of the drug on relative enhancement ratio of the liver	Use of quantitative variables extracted from MRI data Effect size displayed as (%) calculated as = 100* (Relative enhancement ratio with drug- Relative enhancement ratio without drug)/(Relative enhancement ratio without drug) Area under the curve, mM*sec; liver concentrations, mL/100cm3)	Visit B which is performed at baseline, Visit C which is performed within 56 days of baseline visit B
Evaluate effect size of the drug on area under the curve in blood concentrations.	Use of quantitative variables extracted from MRI data Effect size displayed as (%) and calculated as = 100* (Area under the curve blood concentration with drug- Area under the curve blood concentration without drug)/(Area under the curve blood concentration without drug) Area under the curve units are (mM*sec)	Visit B which is performed at baseline, Visit C which is performed within 56 days of baseline visit B
Evaluate the effect size of the drug on liver concentrations.	Effect size displayed as (%) and calculated as = 100* (Area under the curve liver concentration with drug- Area under the curve liver concentration without drug)/(Area under the curve liver concentration without drug) (liver concentrations, (mL/100cm3))	Visit B which is performed at baseline, Visit C which is performed within 56 days of baseline visit B
Diurnal variations in uptake rates in the absence of an intervention	quantitative variables extracted from the MRI data. 95% CI on the mean effect size of uptake rate khe (mL/min/100mL)	Visit B which is performed at baseline
Diurnal variations in excretion rates in the absence of an intervention	quantitative variables extracted from the MRI data. 95% CI on the mean effect size of excretion rate kbh (mL/min/100mL	Visit B which is performed at baseline

Collaborators and Investigators

• Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
• Collaborators: University of Sheffield
• Investigators: Principal Investigator: Benjamin Rea, Sheffield Teaching Hospital

Publications and helpful links

General Publications

• Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705. doi: 10.1111/j.1476-5381.2009.00430.x. Epub 2009 Sep 25.
• Melillo N, Scotcher D, Kenna JG, Green C, Hines CDG, Laitinen I, Hockings PD, Ogungbenro K, Gunwhy ER, Sourbron S, Waterton JC, Schuetz G, Galetin A. Use of In Vivo Imaging and Physiologically-Based Kinetic Modelling to Predict Hepatic Transporter Mediated Drug-Drug Interactions in Rats. Pharmaceutics. 2023 Mar 10;15(3):896. doi: 10.3390/pharmaceutics15030896.
• Ruan G, Wu F, Shi D, Sun H, Wang F, Xu C. Metformin: update on mechanisms of action on liver diseases. Front Nutr. 2023 Dec 14;10:1327814. doi: 10.3389/fnut.2023.1327814. eCollection 2023.
• Gertz M, Cartwright CM, Hobbs MJ, Kenworthy KE, Rowland M, Houston JB, Galetin A. Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential. Pharm Res. 2013 Mar;30(3):761-80. doi: 10.1007/s11095-012-0918-y. Epub 2012 Nov 22.

Study record dates

Study Major Dates

• Study Start (Actual): December 2, 2024
• Primary Completion (Actual): February 28, 2025
• Study Completion (Actual): February 28, 2025

Study Registration Dates

• First Submitted: July 8, 2025
• First Submitted That Met QC Criteria: April 14, 2026
• First Posted (Actual): April 21, 2026

Study Record Updates

• Last Update Posted (Actual): April 21, 2026
• Last Update Submitted That Met QC Criteria: April 14, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: MRI; liver; imaging biomarker; Gadoxetate
• Additional Relevant MeSH Terms: Digestive System Diseases; Liver Diseases
• Other Study ID Numbers: STH23320; 116106 (Other Grant/Funding Number: The Innovative Medicines Initiative)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Anonymised MRI data will be electronically transferred to the study investigators Bioxydyn Ltd for independent analysis of the findings. Consortium agreement is established between the two sites. Anonymised data will also be made available for secondary research, educational or commercial purposes by third-party investigators from the private or public sector.

IPD Sharing Time Frame

All data collated or generated during this research study will be stored short term on an encrypted shared Drive (administered by university IT) with only the investigators and research fellows having access. Upon completion of the research activities all data will be deleted from this short term storage and will be stored, fully anonymised, in a long-term repository.

A digitally encrypted key file, linking Study ID to participant names, date of birth and contact details, will be stored on the local STH drives, separate from all other study data. The key file will be securely stored for 5 years at the end of the study, after all MRI scans on all participants have been completed.

Upon completion of the study, imaging data will be fully anonymised and stored in the university-owned Google Drive. Anonymous data may be made publicly available on zenodo.org in the future, also serving as a long-term repository.

IPD Sharing Access Criteria

All data collated or generated during this research study will be stored short term on an encrypted shared Drive (administered by university IT) with only the investigators and research fellows having access.

At the end of each scan, MRI data will be exported anonymously using the participant's Study ID. Anonymised MR images will be exported in DICOM (Digital Imaging and Communication) format to the shared encrypted research group University of Sheffield Google Drive for primary analysis. Data for primary analysis will be performed with in-house software on an encrypted University of Sheffield computer.

• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; ICF

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No